Search Results - "VAN HAGEN, Pieter"

Impact of a multidisciplinary tumour board meeting for upper-GI malignancies on clinical decision making: a prospective cohort study by van Hagen, Pieter, Spaander, Manon C. W., van der Gaast, Ate, van Rij, Caroline M., Tilanus, Hugo W., van Lanschot, J. Jan B., Wijnhoven, Bas P. L.

“…Background/aims The Dutch guidelines for diagnosis and treatment of upper-GI malignancies recommend review of patients by a multidisciplinary tumour board…”
Get full text

Validation of a Nomogram Predicting Complications After Esophagectomy for Cancer by Grotenhuis, Brechtje A., MD, van Hagen, Pieter, MD, Reitsma, Johannes B., MD, PhD, Lagarde, Sjoerd M., MD, PhD, Wijnhoven, Bas P.L., MD, PhD, van Berge Henegouwen, Mark I., MD, PhD, Tilanus, Hugo W., MD, PhD, van Lanschot, J. Jan B., MD, PhD

“…Background A nomogram has been developed recently in order to predict the occurrence and severity of postoperative complications after esophagectomy for…”
Get full text

Patterns of Recurrence After Surgery Alone Versus Preoperative Chemoradiotherapy and Surgery in the CROSS Trials by OPPEDIJK, Vera, VAN DER GAAST, Ate, REINDERS, Janny G, RICHEL, Dick J, VAN BERGE HENEGOUWEN, Mark I, HULSHOF, Maarten C. C. M, VAN LANSCHOT, Jan J. B, VAN HAGEN, Pieter, VAN OS, Rob, VAN RIJ, Caroline M, VAN DER SANGEN, Maurice J, BEUKEMA, Jannet C, RÜTTEN, Heidi, SPRUIT, Patty H

“…To analyze recurrence patterns in patients with cancer of the esophagus or gastroesophageal junction treated with either preoperative chemoradiotherapy (CRT)…”
Get full text

Effect of Neoadjuvant Chemoradiotherapy on Health-Related Quality of Life in Esophageal or Junctional Cancer: Results From the Randomized CROSS Trial by Noordman, Bo Jan, Verdam, Mathilde G E, Lagarde, Sjoerd M, Hulshof, Maarten C C M, van Hagen, Pieter, van Berge Henegouwen, Mark I, Wijnhoven, Bas P L, van Laarhoven, Hanneke W M, Nieuwenhuijzen, Grard A P, Hospers, Geke A P, Bonenkamp, Johannes J, Cuesta, Miguel A, Blaisse, Reinoud J B, Busch, Olivier R, Ten Kate, Fiebo J W, Creemers, Geert-Jan M, Punt, Cornelis J A, Plukker, John Th M, Verheul, Henk M W, Spillenaar Bilgen, Ernst J, van Dekken, Herman, van der Sangen, Maurice J C, Rozema, Tom, Biermann, Katharina, Beukema, Jannet C, Piet, Anna H M, van Rij, Caroline M, Reinders, Janny G, Tilanus, Hugo W, Steyerberg, Ewout W, van der Gaast, Ate, Sprangers, Mirjam A G, van Lanschot, J Jan B

“…Purpose To compare pre-agreed health-related quality of life (HRQOL) domains in patients with esophageal or junctional cancer who received neoadjuvant…”
Get full text

Comparison of the 6th and 7th Editions of the UICC-AJCC TNM Classification for Esophageal Cancer by Talsma, Koen, van Hagen, Pieter, Grotenhuis, Brechtje A., Steyerberg, Ewout W., Tilanus, Hugo W., van Lanschot, Jan J. B., Wijnhoven, Bas P. L.

“…Background The new 7th edition of the Union for International Cancer Control–American Joint Committee on Cancer (UICC-AJCC) tumor, node, metastasis (TNM)…”
Get full text

Study on 3D High-Resolution Anorectal Manometry Interrater Agreement in the Evaluation of Dyssynergic Defecation Disorders by van Oostendorp, Justin Y, van Hagen, Pieter, van der Mijnsbrugge, Grietje J. H, Han-Geurts, Ingrid J. M

“…Anorectal manometry measurements exhibit significant interrater variability. Newer techniques like 3D high-resolution anorectal manometry (3D-HRAM) have the…”
Get full text

IgG4-related diseases: state of the art on clinical practice guidelines by Iaccarino, Luca, Talarico, Rosaria, Scirè, Carlo Alberto, Amoura, Zahir, Burmester, Gerd, Doria, Andrea, Faiz, Karim, Frank, Charissa, Hachulla, Eric, Hie, Miguel, Launay, David, Montecucco, Carlomaurizio, Monti, Sara, Mouthon, Luc, Tincani, Angela, Toniati, Paola, Van Hagen, Pieter Martin, Van Vollenhoven, Ronald F, Bombardieri, Stefano, Mueller-Ladner, Ulf, Schneider, Matthias, Smith, Vanessa, Cutolo, Maurizio, Mosca, Marta, Alexander, Tobias

“…Immunoglobulin G4-related diseases (IgG4-RD) are a group of chronic relapsing–remitting inflammatory conditions, characterised by tissue infiltration with…”
Get full text

Residual Esophageal Cancer after Neoadjuvant Chemoradiotherapy Frequently Involves the Mucosa and Submucosa by Shapiro, Joel, ten Kate, Fiebo J. W., van Hagen, Pieter, Biermann, Katharina, Wijnhoven, Bas P. L., van Lanschot, J. Jan B.

Get full text

Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial by Eyck, Ben M, van Lanschot, J Jan B, Hulshof, Maarten C C M, van der Wilk, Berend J, Shapiro, Joel, van Hagen, Pieter, van Berge Henegouwen, Mark I, Wijnhoven, Bas P L, van Laarhoven, Hanneke W M, Nieuwenhuijzen, Grard A P, Hospers, Geke A P, Bonenkamp, Johannes J, Cuesta, Miguel A, Blaisse, Reinoud J B, Busch, Olivier R, Creemers, Geert-Jan M, Punt, Cornelis J A, Plukker, John Th M, Verheul, Henk M W, Spillenaar Bilgen, Ernst J, van der Sangen, Maurice J C, Rozema, Tom, Ten Kate, Fiebo J W, Beukema, Jannet C, Piet, Anna H M, van Rij, Caroline M, Reinders, Janny G, Tilanus, Hugo W, Steyerberg, Ewout W, van der Gaast, Ate

“…Preoperative chemoradiotherapy according to the chemoradiotherapy for esophageal cancer followed by surgery study (CROSS) has become a standard of care for…”
Get full text

Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial by Shapiro, Joel, Dr, van Lanschot, J Jan B, Prof, Hulshof, Maarten C C M, MD, van Hagen, Pieter, MD, van Berge Henegouwen, Mark I, MD, Wijnhoven, Bas P L, MD, van Laarhoven, Hanneke W M, Prof, Nieuwenhuijzen, Grard A P, MD, Hospers, Geke A P, Prof, Bonenkamp, Johannes J, MD, Cuesta, Miguel A, Prof, Blaisse, Reinoud J B, MD, Busch, Olivier R C, Prof, ten Kate, Fiebo J W, Prof, Creemers, Geert-Jan M, MD, Punt, Cornelis J A, Prof, Plukker, John Th M, Prof, Verheul, Henk M W, Prof, Bilgen, Ernst J Spillenaar, MD, van Dekken, Herman, MD, van der Sangen, Maurice J C, MD, Rozema, Tom, MD, Biermann, Katharina, MD, Beukema, Jannet C, MD, Piet, Anna H M, MD, van Rij, Caroline M, MD, Reinders, Janny G, MD, Tilanus, Hugo W, Prof, Steyerberg, Ewout W, Prof, van der Gaast, Ate, MD

“…Summary Background Initial results of the ChemoRadiotherapy for Oesophageal cancer followed by Surgery Study (CROSS) comparing neoadjuvant chemoradiotherapy…”
Get full text

Residual Esophageal Cancer after Neoadjuvant Chemoradiotherapy Frequently Involves the Mucosa and Submucosa by Shapiro, Joel, ten Kate, Fiebo J W, van Hagen, Pieter, Biermann, Katharina, Wijnhoven, Bas P L, van Lanschot, J. Jan B

“…OBJECTIVES:To gain insight into the exact location of residual esophageal cancer in the esophageal wall and regional lymph nodes after neoadjuvant…”
Get full text

Lymph Node Retrieval During Esophagectomy With and Without Neoadjuvant Chemoradiotherapy: Prognostic and Therapeutic Impact on Survival by Talsma, A. Koen, Shapiro, Joel, Looman, Caspar W. N., van Hagen, Pieter, Steyerberg, Ewout W., van der Gaast, Ate, van Berge Henegouwen, Mark I., Wijnhoven, Bas P. L., van Lanschot, J. Jan B.

“…We aimed to examine the association between total number of resected nodes and survival in patients after esophagectomy with and without nCRT. Most studies…”
Get full text

Using the Comprehensive Complication Index to Assess the Impact of Neoadjuvant Chemoradiotherapy on Complication Severity After Esophagectomy for Cancer by Nederlof, Nina, Slaman, Annelijn E., van Hagen, Pieter, van der Gaast, Ate, Slankamenac, Ksenija, Gisbertz, Suzanne S., van Lanschot, Jan J. B., Wijnhoven, Bas P. L., van Berge Henegouwen, Mark I.

“…Background Neoadjuvant chemoradiotherapy (nCRT) followed by surgery for patients with esophageal or junctional cancer has become a standard of care. The…”
Get full text

Prolonged Time to Surgery After Neoadjuvant Chemoradiotherapy Increases Histopathological Response Without Affecting Survival in Patients With Esophageal or Junctional Cancer by Shapiro, Joel, van Hagen, Pieter, Lingsma, Hester F., Wijnhoven, Bas P. L., Biermann, Katharina, ten Kate, Fiebo J. W., Steyerberg, Ewout W., van der Gaast, Ate, van Lanschot, J. Jan B.

“…To determine the relation between time to surgery (TTS) after neoadjuvant chemoradiotherapy (nCRT) and pathologically complete response (pCR), surgical…”
Get full text

Delay in Diagnostic Workup and Treatment of Esophageal Cancer by Grotenhuis, Brechtje A., van Hagen, Pieter, Wijnhoven, Bas P. L., Spaander, Manon C. W., Tilanus, Hugo W., van Lanschot, Jan J. B.

“…Introduction Esophageal cancer should preferably be detected and treated at an early stage, but this may be prohibited by late onset of symptoms and delays in…”
Get full text

Location of Lymph Node Involvement in Patients with Esophageal Adenocarcinoma Predicts Survival by Talsma, Aaldert K., Ong, Chin-Ann J., Liu, Xinxue, van Hagen, Pieter, Van Lanschot, Jan J. B., Tilanus, Huug W., Hardwick, Richard H., Carroll, Nicholas R., Spaander, Manon C. W., Fitzgerald, Rebecca C., Wijnhoven, Bas P. L.

“…Background The location of positive lymph nodes has been abandoned in the seventh classification of the TNM staging system for esophageal adenocarcinoma. The…”
Get full text

O200 10-YEAR FOLLOW-UP OF A RANDOMISED CONTROLLED TRIAL COMPARING NEOADJUVANT CHEMORADIOTHERAPY PLUS SURGERY VERSUS SURGERY ALONE FOR OESOPHAGEAL OR JUNCTIONAL CANCER (CROSS) by Eyck, Ben M, van Lanschot, J Jan B, Hulshof, Maarten C C M, van der Wilk, Berend J, Shapiro, Joel, van Hagen, Pieter, Nieboer, Daan, van Berge Henegouwen, Mark I, Wijnhoven, Bas P L, van Laarhoven, Hanneke W M, Nieuwenhuijzen, Grard A P, Hospers, Geke A P, Bonenkamp, Johannes J, Cuesta, Miguel A, Blaisse, Reinoud J B, Busch, Olivier R, ten Kate, Fiebo J W, Creemers, Geert-Jan M, Punt, Cornelis J A, Plukker, John Th M, Verheul, Henk M W, Spillenaar Bilgen, Ernst J, van Dekken, Herman, van der Sangen, Maurice J C, Rozema, Tom, Biermann, Katharina, Beukema, Jannet C, Piet, Anna H M, van Rij, Caroline M, Reinders, Janny G, Tilanus, Hugo W, van der Gaast, Ate

“…Abstract Aim To report the long term results of the CROSS trial with a minimum follow-up of 10 years. Background Neoadjuvant chemoradiotherapy according to the…”
Get full text

Prediction of disease-free survival using relative change in FDG-uptake early during neoadjuvant chemoradiotherapy for potentially curable esophageal cancer: A prospective cohort study by Hagen, P. v., Heijl, M. v., Henegouwen, M. I. v. B., Boellaard, R., Bossuyt, P. M. M., Kate, F. J. W. t., Dekken, H. v., Hoekstra, O. S., Sloof, G. W., Lanschot, J. J. B. v.

“…SUMMARY 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) has been investigated as a tool for monitoring response to neoadjuvant chemo- and…”
Get full text

Preoperative Chemoradiotherapy for Esophageal Cancer by Power, Derek G, O'Sulleabhain, Criostoir, Murphy, Thomas J, Matzdorff, Axel C, Julià, David, Gómez, Núria, Codina-Cazador, Antoni, van Hagen, Pieter, van Lanschot, Joseph J.B, van der Gaast, Ate

“…To the Editor: Van Hagen et al. (May 31 issue) 1 found, after a median follow-up of almost 4 years, that preoperative chemoradiotherapy with weekly carboplatin…”
Get full text

Validation of a Nomogram Predicting Complications After Esophagectomy for Cancer. Commentary by GROTENHUIS, Brechtje A, VAN HAGEN, Pieter, REITSMA, Johannes B, LAGARDE, Sjoerd M, WIJNHOVEN, P. L, VAN BERGE HENEGOUWEN, Mark I, TILANUS, Hugo W, VAN LANSCHOT, J. Jan B, FERGUSON, Mark K

Get full text